Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

3SBio Forms China Partnership with Verseau for Macrophage Checkpoint Modulators

publication date: Feb 11, 2019

3SBio of Shenyang invested $15 million into Boston's Verseau Therapeutics and will partner with Verseau to develop its macrophage checkpoint modulators (MCMs) in Greater China for various cancers. 3SBio will be responsible for antibody development, GMP manufacturing and commercialization in China, Taiwan, Hong Kong and Macau, while Verseau will supply the targets. 3SBio and Verseau will each be eligible to receive milestone payments and sales-based royalties, though details of the agreement were not disclosed. More details....

Stock Symbol: (HK:1530)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai , China
May 8-9, 2019
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China